Scholarlink

<p>During the European Society for Medical Oncology (ESMO) 2024 scientific meeting, multiple groundbreaking trials from organ-specific studies were reported. Additionally, results from early clinical trials in the tumor-agnostic space, such as the ROME trial and MTA-cooperative PRMT5 inhibition, garnered significant attention and were presented at the Presidential Symposium. The aim of this manuscript is to provide a concise summary of the pan-tumor highlights from ESMO 2024, focusing on developmental therapeutics and novel treatment strategies beyond a specific organ site.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Best of ESMO: pan-tumor highlights

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月22日

查看全文
  • Thorsten Füreder

摘要

During the European Society for Medical Oncology (ESMO) 2024 scientific meeting, multiple groundbreaking trials from organ-specific studies were reported. Additionally, results from early clinical trials in the tumor-agnostic space, such as the ROME trial and MTA-cooperative PRMT5 inhibition, garnered significant attention and were presented at the Presidential Symposium. The aim of this manuscript is to provide a concise summary of the pan-tumor highlights from ESMO 2024, focusing on developmental therapeutics and novel treatment strategies beyond a specific organ site.